AnaptysBio reports $1B Jemperli sales, FDA approval for rectal cancer, and ongoing GSK litigation update

AnaptysBio announced $1 billion in global net sales for Jemperli through September 2026, marking 29% growth year-over-year. Jemperli received FDA approval as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer, expanding its market potential. The company is also awaiting a judgment in its litigation with GSK and Tesaro expected in Q4 2026 or Q1 2027, while preparing for the FDA decision on Quimilza in December 2026. Financially, AnaptysBio reported $30.3 million in collaboration revenue for Q1 2027 and net income of $3.9 million, with ongoing legal costs impacting expenses.

The article highlights AnaptysBio's strong sales growth and upcoming FDA decisions, which could influence related health sector stocks. On Pluang, GSK shares trade at USD 50.59 as of Nov 13, 2026 04:11 WIB, showing a slight 0.02% decrease in one day. GSK's market capitalization stands at $100.96 billion, reflecting its significant presence in the health sector.